CISN - The OMICS Revolution and Beyond - Genomics - pg. 2
| You Are Here: Home > Cancer Research > What We Know About Cancer > OMICS Revolution > Genomics - pg. 3 |
Genomics - Page 3Functional GenomicsThe words of Winston Churchill, spoken in 1942 after three years of war, capture well this stage of the human genomic era: "Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning." The avalanche of genome data grows daily. The new challenge will be to use this vast reservoir of data to explore how DNA and proteins work with each other and the environment to create complex, dynamic living systems. Systematic studies of function on a grand scale-functional genomics-will be the focus of biological explorations in this century and beyond. These explorations will encompass studies in other "omics" such as:
The Future of Genome-Based ResearchRapid progress in genome science and a glimpse into its potential applications have spurred observers to predict that biology will be the foremost science of the 21st century. |
| Section Index | |
| ● | What We Know About Cancer |
| How Cancer is Studied | |
| Drug Development | |
| New Treatments | |
| Research Advocacy | |
Genome-based research is already enabling medical researchers to develop more effective diagnostic tools, better understand the health needs of people based on their individual genetic make-ups, and design new treatments for disease. Thus, the role of genetics in health care is starting to change profoundly and the first examples of the era of personalized medicine are on the horizon:
It is important to realize, however, that it often takes considerable time, effort, and funding to move discoveries from the scientific laboratory into the medical clinic. Most new drugs based on genome-based research are estimated to be at least 10 to 15 years away from general use. According to biotechnology experts, it usually takes more than a decade for a pharmaceutical company to conduct the kinds of clinical studies needed to receive approval from the Food and Drug Administration. Screening and diagnostic tests, however, are expected to be developed and in use more quickly. Rapid progress is also anticipated in the emerging field of pharmacogenomics, which involves using information about a patient's genetic makeup to better tailor drug therapy to their individual needs. Ethical Issues in GenomicsGenomic research may greatly change the practice of health care. But genomic research alone is not enough to enable application of this new knowledge to improvements in human health. We need to carefully study the many ethical, legal and social issues raised by this research. Such study is crucial in order to use genomic research to help patients and prevent misuse of new genetic technologies and information. Many people see this as a balance between the rights of the individual and future individuals. Others see this as much more of a black and white choice. A few issues are listed below:
Because all these new issues are emerging, the U.S. Department of Energy (DOE) and the National Institutes of Health (NIH) have devoted 3% to 5% of their annual Human Genome Project (HGP) budgets toward studying the ethical, legal, and social issues (ELSI) surrounding availability of genetic information. This represents the world's largest bioethics program, which has become a model for ELSI programs around the world. |
||||||||

